ClinicalTrials.gg
Active, not recruitingNCT02135042Updated Nov 12, 2026

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

A Phase 2/3 interventional study of Bone Scan and Cisplatin in EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7 and Stage III Nasopharyngeal Carcinoma AJCC v7, sponsored by NRG Oncology. Active, not recruiting at 213 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by NRG Oncology · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
924
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Epstein-Barr Virus Infections with a site in United States — 19 open to participants now, 25 under way, 2 of them phase 3. Epstein-Barr Virus Infections · United States.

Planned enrollment
3rd of 63
924 · median 25
Started
2014
with 6 others
Phase 2/3
3 of 76
none open now
Primary completion
2029-01
later than 17 of 23 live
Registered
36th of 76
by date

Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, this one is the 3rd largest by planned enrollment of the 63 interventional ones that give a count, is one of 7 that started in 2014, is one of 3 in phase 2/3, reaches primary completion later than 17 of the 23 other live ones, and was the 36th registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

19 of the 76 studies in Epstein-Barr Virus Infections with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Epstein-Barr Virus Infections with a site in United States, or all of them as a file.
02

Study summary

There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine whether substituting adjuvant concurrent high dose cisplatin (CDDP) and fluorouracil (5-FU) with gemcitabine (gemcitabine hydrochloride) and paclitaxel will result in superior progression-free survival. (Detectable Plasma Epstein Barr Virus [EBV] Deoxyribonucleic Acid [DNA] Cohort randomized Phase II) II. To determine whether omitting adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in non-inferior overall survival as compared with those patients receiving adjuvant CDDP and 5-FU chemotherapy. (Undetectable Plasma EBV DNA Cohort Phase III)

SECONDARY OBJECTIVES:

I. Time to distant metastasis. (Randomized Phase II and Phase III) II. Time to local progression. (Randomized Phase II and Phase III) III. Time to regional progression. (Randomized Phase II and Phase III) IV. Progression-free survival (Undetectable Cohort). V. Overall survival (Detectable Cohort). VI. Acute and late toxicity profiles based on clinician-reported Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4. (Randomized Phase II and Phase III) VII. Death during or within 30 days of end of protocol treatment. (Randomized Phase II and Phase III) VIII. Quality of life (general and physical well-being). (Randomized Phase II and Phase III) IX. Quality of life (hearing). (Randomized Phase II and Phase III) X. Quality of life (peripheral neuropathy). (Randomized Phase II and Phase III) XI. Cost effectiveness. (Randomized Phase II and Phase III)

OUTLINE:

Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) 5 days a week for 6.5 to 7 weeks and receive low-dose cisplatin intravenously (IV) over 30-60 minutes or high-dose cisplatin IV over 3 hours once weekly during IMRT. Beginning 1 week after chemoradiation, plasma samples are collected for EBV DNA analysis.

PHASE II: Patients with detectable EBV DNA from pre-treatment analysis are randomized to 1 of 2 treatment arms.

ARM I: Patients receive PF regimen comprising cisplatin IV over 60-180 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

PHASE III:

Patients with undetectable EBV DNA from pre-treatment analysis are randomized to 1 of 2 treatment arms.

ARM III: Patients receive PF regimen as in Arm I.

ARM IV: Patients undergo clinical observation.

Patients undergo computed tomography (CT) scan, magnetic resonance imaging, (MRI) positron emission tomography (PET) scan, and bone scan throughout the study.

03

Conditions studied

  • EBV Infection
  • Stage II Nasopharyngeal Carcinoma AJCC v7
  • Stage III Nasopharyngeal Carcinoma AJCC v7
  • Stage IVA Nasopharyngeal Carcinoma AJCC v7
  • Stage IVB Nasopharyngeal Carcinoma AJCC v7
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx
  • Sites are required to complete Step 1 registration before submitting specimens for EBV DNA analysis

    • Patients must have detectable pretreatment plasma EBV DNA, determined by the central lab prior to Step 2 registration
    • For patients who have detectable plasma EBV DNA tested at one of the credentialed central labs within 28 days prior to Step 1 registration: that test result can be used for eligibility without the need for re-testing; to use this test result for eligibility, the central lab must enter the test result through the pathology portal
  • Stage II-IVB disease (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) with no evidence of distant , based upon the following minimum diagnostic workup:

    • History/physical examination by a Medical Oncologist or Clinical Oncologist or Radiation Oncologist or Ear, Nose, Throat specialist (ENT), which must include an endoscopic evaluation, a complete list of current medications, and assessment of weight and weight loss in the past 6 months within 21 days prior to registration
    • Evaluation of tumor extent required within 28 days prior to registration:

      • Magnetic resonance imaging (MRI) of the nasopharynx and neck; or computed tomography (CT) of the nasopharynx and neck with =\< 3 mm contiguous slices with contrast and bone windows (to evaluate base of skull involvement).

        • Note: If a treatment planning CT scan is used, it must be with =\< 3 mm contiguous slices with contrast and be read by a radiologist
    • To rule out distant metastasis, patients must undergo the following imaging within 28 days prior to registration:

      • A CT scan with contrast of the chest and abdomen (required), and the pelvis (optional), or a total body PET/CT scan (non-contrast PET/CT is acceptable)
      • A bone scan only when there is suspicion of bone metastases (a PET/CT scan can substitute for the bone scan)
  • Zubrod performance status 0-1 within 21 days prior to registration
  • Age >= 18
  • (ANC) >= 1,500 cells/mm\^3 (within 21 days prior to registration)
  • >= 100,000 cells/mm\^3 (within 21 days prior to registration)
  • >= 8.0 g/dl (within 21 days prior to registration) (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
  • Total =\< 1.5 x institutional (ULN) (within 21 days prior to registration)
  • (AST) and alanine aminotransferase (ALT) =\< 1.5 x institutional ULN (within 21 days prior to registration)
  • Alkaline phosphatase =\< 1.5 x institutional ULN (within 21 days prior to registration)
  • Serum creatinine =\< 1.5 mg/dl or calculated (CC) >= 50 ml/min determined by 24-hour urine collection or estimated by Cockcroft-Gault formula (within 21 days prior to registration)
  • Negative serum pregnancy test within 14 days prior to registration for women of
  • Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of throughout protocol treatment
  • Patient must provide study specific prior to study entry, including the mandatory pre-treatment plasma EBV DNA assay

Exclusion criteria

Exclusion Criteria:

  • Prior invasive (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable; however, at least 6-weeks recovery is necessary if the last regimen included nitrosourea or mitomycin
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • Patients with hearing loss assessed to be primarily sensorineural in nature, requiring a hearing aid, or intervention (i.e. interfering in a way with activities of daily living); a conductive hearing loss that is tumor-related is allowed
  • >= Grade 2 peripheral sensory neuropathy (, v. 4.0)
  • Severe, active co-morbidity, defined as follows:

    • Major medical or psychiatric illness, which in the investigator's opinion would interfere with the completion of therapy and follow up or with full understanding of the risks and potential complications of the therapy
    • Unstable angina and/or uncontrolled congestive heart failure within past 6 months
    • Myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; note that patients switched from IV antibiotics and currently on oral antibiotics whose infection is assessed to be adequately treated or controlled are eligible
    • exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that (HIV) testing is not required for entry into this protocol
  • Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of
  • Prior allergic reaction to the study drug(s) involved in this protocol
  • Patients with undetectable pre-treatment plasma EBV DNA
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
924 participants (estimated)

Study arms

  • Active comparator
    Phase I, Arm I (chemoradiation, cisplatin, fluorouracil)

    Patients receive PF regimen comprising cisplatin IV over 60-180 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study.

    Procedure: Bone Scan · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Fluorouracil · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment

  • Experimental
    Phase I, Arm II (chemoradiation, gemcitabine, paclitaxel)

    Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study.

    Procedure: Bone Scan · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Gemcitabine Hydrochloride · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment

  • Active comparator
    Phase II, Arm III (chemoradiation, cisplatin, fluorouracil)

    Patients receive PF regimen as in Arm I of Phase II.Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study.

    Procedure: Bone Scan · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Fluorouracil · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment

  • Experimental
    Phase II, Arm IV (chemoradiation, observation)

    Patients undergo clinical observation. Patients undergo CT scan, MRI,PET scan, and bone scan throughout the study.

    Procedure: Bone Scan · Drug: Cisplatin · Other: Clinical Observation · Procedure: Computed Tomography · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment

Interventions

  • ProcedureBone Scan

    Undergo bone scan

    Also known as: Bone Scintigraphy

  • Given IV

    Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin

  • OtherClinical Observation

    Undergo clinical observation

    Also known as: observation

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757

  • DrugGemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

    Also known as: IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) (Detectable Plasma Epstein Barr virus [EBV] deoxyribonucleic acid [DNA] Cohort Phase II)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. A one-sided log rank test will be used to compare the PFS at a significance level of 0.1379.

    Time frame: Up to 7 years

  2. Overall survival (OS) (Undetectable Plasma EBV DNA Cohort Phase III)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose. The confidence interval approach will be used for the final analysis of OS.

    Time frame: Up to 7 years

Secondary outcomes

  1. Time to distant metastasis (DM) (Phase II and III)

    The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.

    Time frame: Up to 7 years

  2. Time to local progression (Phase II and III)

    The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.

    Time frame: Up to 7 years

  3. Time to regional progression (Phase II and III)

    Defined as an estimated increase in the size of the tumor (product of the perpendicular diameters of the two largest dimensions) of greater than 25%, taking as reference the smallest value of all previous measurements or appearance of new areas of malignant disease. The cumulative incidence method will be used to estimate local, regional, and distant failure rates. The failure rates for the experimental treatment will be compared against the control using a failure-specific log-rank test. Multivariate analysis will be performed using the Cox proportional hazards model.

    Time frame: Up to 7 years

  4. Progression-free survival (PFS) (Undetectable Plasma EBV DNA Cohort Phase III)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose.

    Time frame: Up to 7 years

  5. Overall survival (OS) (Detectable Plasma EBV DNA Cohort Phase II)

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a 1-sided stratified log rank test. for stratification factors and concurrent cisplatin dose.

    Time frame: Up to 7 years

  6. Incidence of acute grade 3-5 adverse events (Phase II and III)

    Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.

    Time frame: Up to 7 years

  7. Incidence of late grade 3-5 adverse events (Phase II and III)

    Rates of specific acute toxicity profiles and late toxicity profiles will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.

    Time frame: Up to 7 years

  8. Incidence of death (Phase II and III)

    Incidence of death will be determined.

    Time frame: Up to 30 days of end of protocol treatment

  9. Changes in pure tone audiometry (Phase II and III)

    Correlation between categorical measures will be summarized by odds ratios, chi-square tests, and associated measures. Adjusted correlation may be derived from analysis of covariance (ANCOVA) models or derived directly using nonparametric analysis of variance (ANOVA) models if normality assumption is violated. Correlations between HHIE-S PRO scores and PTA and FACT-NP hearing, and PTA will be compared as dependent statistics

    Time frame: Baseline to up to 1 year

  10. Changes in quality of life (QOL) (general and physical well-being) (Phase II and III)

    Will be assessed using the Functional Assessment of Cancer Therapy (FACT)-Nasopharyngeal (NP). Changes in patient reported outcome (PRO) scores will be correlated to clearance or non-clearance of EBV titers. Descriptive statistics derived from FACT-NP will be used to enrich the understanding of QOL as it pertains to the 2 phase III arms of observation versus additional adjuvant chemotherapy. Univariable and multivariable analysis will be performed using the Cox proportional hazards model for OS and distant metastasis. Pearson correlation will be estimated between general and physical well-being. QOL measures and change from baseline will be correlated to EBV DNA.

    Time frame: Baseline to up to 24 months

  11. Changes in quality of life (QOL) (hearing) (Phase II and III)

    Will be assessed by the Hearing Handicap Inventory for the Elderly-Screening version (HHIE-S). QOL analysis including overall score and change from baseline will be summarized using mean and standard deviation at each time point for each arm. Overall and nasopharyngeal-specific QOL, hearing QOL (FACT-NP hearing domain, HHIE-S scores), peripheral neuropathy QOL over the short and long term and pure-tone audiometry (PTA) scores will be compared using a two sample independent t test and paired t test if the comparison is within the experimental arm between different time points.

    Time frame: Baseline to up to 24 months

  12. Changes in quality of life (QOL) (peripheral neuropathy) as assessed by the Functional Assessment of Cancer Therapy (FACT)-Taxane (Phase II and III)

    Changes in QOL (peripheral neuropathy) will be assessed by the Functional Assessment of Cancer Therapy (FACT)-Taxane.

    Time frame: Baseline to up to 24 months

  13. Cost effectiveness as assessed by the health-related quality of life (QOL) (HRQOL) from the EuroQol (EQ-5D) instrument (Phase II and III)

    Incremental cost effectiveness ratios will be compared to determine the probability of cost effectiveness of various interventions, with sensitivity analyses to identify model weaknesses. The expected value of perfect information will be determined to delimit the upper boundary for cost-effective future investment in this area of research.

    Time frame: Up to 24 months

07

Study locations

213 sites

Showing the first 100 of 213 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, Brizel DM, Busse PM, Caudell JJ, Durm G, Fakhry C, Galloway T, Geiger JL, Gillison ML, Glastonbury C, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Juloori A, Kase M, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Price K, Rocco JW, Rodriguez CP, Schwartz D, Shah JP, Sher D, John MS, Wang H, Weinstein G, Worden F, Bruce JY, Yom SS, Zhen W, Montgomery S, Darlow SD. NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 2.2025. J Natl Compr Canc Netw. 2025 Feb;23(2):2-11. doi: 10.6004/jnccn.2025.0007. PubMed 39938471 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2014 (actual). Primary completion is estimated for Jan 2029, 174 months after the start.

Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Jan 2029, last on Nov 12, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2031 → Jan 2034, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2014
First posted
May 9, 2014
StartActual
Jul 1, 2014
Primary completionEst.
Jan 31, 2029was Dec 2026
CompletionEst.
Jan 1, 2034was Dec 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2026→Jan 31, 2029
moved 2 times, Oct 13, 2026 – Nov 12, 2026
Study completion
Dec 1, 2031→Jan 1, 2034
Oct 13, 2026
Show all 2 updates
  1. Nov 12, 2026
    Primary completion Jan 1, 2029→Jan 31, 2029
    + 2 other changes: verification date and site details
  2. Oct 13, 2026
    Primary completion Dec 1, 2026→Jan 1, 2029
    Study completion Dec 1, 2031→Jan 1, 2034
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02135042
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
May 9, 2014
Start date
Jul 1, 2014
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 1, 2034 (estimated)
Last update
Nov 12, 2026

Study contacts

Nancy Y Lee
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Paclitaxel

Start the discussion